NGM · Financial Statements
Vera Therapeutics, Inc. (VERA) Financial Statements
$29.88
NGM: VERA
Market Cap $2.14B
Overview Financials Dividend
Vera Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $300.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $0 $0 $0 $0 $0 Operating Profit $-34.0M $-91.0M $-102.0M $-167.0M $-315.0M Net Profit $-33.0M $-89.0M $-96.0M $-152.0M $-300.0M EPS $-2.43 $-3.35 $-2.25 $-2.75 $-4.66 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $84.0M $131.0M $176.0M $656.0M $735.0M Total Liabilities $14.0M $55.0M $74.0M $79.0M $130.0M Cash $80.0M $43.0M $46.0M $93.0M $355.0M Borrowings $5.0M $31.0M $54.0M $55.0M $77.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $-24.0M $-68.0M $-92.0M $-135.0M $-241.0M Investing Cash Flow $-4.0M $-71.0M $-39.0M $-426.0M $194.0M Financing Cash Flow $-2.0M $-4.0M $-6.0M $-26.0M $-22.0M Net Cash Flow $26.0M $-36.0M $2.0M $47.0M $262.0M Free Cash Flow $-24.0M $-68.0M $-92.0M $-136.0M $-242.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.14 EV / EBITDA -6.08 FCF Yield -14.45% Quick Ratio 10.92 Interest Coverage -36.93 Return 1Y 61.75% Return 3Y 115.77% Return 5Y 104.86%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .